South Korean pharmaceutical company, GC Biopharma Co has obtained approval from the Indonesian Ministry of Health for the establishment of a blood products facility. The Indonesian government has been actively seeking business rights to domestically produce blood products, aiming to decrease reliance on imports. With a population of more than 250 million, Indonesia currently relies entirely on imported blood products.
Developing domestic production capabilities is crucial for meeting healthcare needs, addressing emergencies, ensuring national health security, and achieving cost-effectiveness in healthcare. Local production would enhance healthcare quality and provide timely, affordable, and accessible blood products to the Indonesian population. Hence, the supply of blood products in Indonesia can be stabilized.
After being chosen as the preferred negotiator in January 2023, GC Biopharma underwent extensive discussions and coordination, ultimately securing official approval. The specific contract size and details will be revealed upon finalization of the contract. In addition, the exact location of the plant has not yet been revealed by the company.
Since the 1970s, GC Biopharma has been engaged in the production of diverse blood products, initially focusing on albumin. The company has also successfully exported blood product plants to Thailand and gained significant expertise in constructing factories in various countries, including China and Canada.
(Source: The Korean Economic Daily)